Halberd (Halberd) Debt-to-EBITDA : -0.34 (As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Halberd's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.00 Mil. Halberd's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.15 Mil. Halberd's annualized EBITDA for the quarter that ended in Jul. 2023 was $-0.45 Mil. Halberd's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2023 was -0.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Halberd's Debt-to-EBITDA or its related term are showing as below:

HALB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.89 Med: -0.34 Max: -0.09
Current: -0.34

During the past 3 years, the highest Debt-to-EBITDA Ratio of Halberd was -0.09. The lowest was -8.89. And the median was -0.34.

HALB's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.35 vs HALB: -0.34

Halberd Debt-to-EBITDA Historical Data

The historical data trend for Halberd's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Debt-to-EBITDA Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Debt-to-EBITDA

-8.89

-0.09

-0.34

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Debt-to-EBITDA	-8.89	-0.09	-0.34

Competitive Comparison of Halberd's Debt-to-EBITDA

For the Biotechnology subindustry, Halberd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Halberd's Debt-to-EBITDA falls into.

Halberd Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Halberd's Debt-to-EBITDA for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0.15)	/	-0.446
	=	-0.34

Halberd's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0.15)	/	-0.446
	=	-0.34

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Jul. 2023) EBITDA data.

Halberd (OTCPK:HALB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Halberd Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Halberd's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236